Gefitinib enhances sensitivity of endometrial cancer cells to progestin therapy via dual-specificity phosphatase 1

In this study, we investigated if Gefitinib, an epidermal growth factor receptor (EGFR) inhibitor, augments endometrial cancer (EC) therapy with medroxyprogesterone acetate (MPA). Combined treatment with Gefitinib plus MPA decreased the proliferation and invasiveness of the Ishikawa and RL952 EC cel...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncotarget
Egile Nagusiak: Yang, Yuan, Zhou, Jingyi, Li, Xiaoping, Zhao, Lijun, Cheng, Yuan, Lin, Yanying, Wang, Jiaqi, Wei, Lihui, Dong, Yafeng, Wang, Jianliu
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Impact Journals LLC 2017
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5777777/
https://ncbi.nlm.nih.gov/pubmed/29383165
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.23264
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak